Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.56 |
| ▸ | HTR2A | P28223 | 7/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8753491 | 0.97 | HRH1 (0.54) | HRH1HTR2ATAAR1KCNH2CYP3A4 | |
| SCHEMBL2096612 | 0.84 | HRH1 (0.60) | HRH1HTR2ATAAR1KCNH2CYP3A4 | |
| SCHEMBL2091869 | 0.82 | HRH1 (0.58) | HRH1HTR2ATAAR1KCNH2SIGMAR1 | |
| SCHEMBL3290730 | 0.82 | HRH1 (0.68) | HRH1HTR2ATAAR1KCNH2CYP3A4 | |
| SCHEMBL4354924 | 0.81 | HRH1 (0.42) | HRH1HTR2ATAAR1CYP2D6LMNA | |
| SCHEMBL3389109 | 0.80 | HRH1 (0.56) | HRH1HTR2ATAAR1SIGMAR1 | |
| SCHEMBL3389409 | 0.80 | HRH1 (0.56) | HRH1HTR2ATAAR1SIGMAR1 | |
| SCHEMBL2732016 | 0.79 | HRH1 (0.65) | HRH1HTR2ATAAR1KCNH2CYP3A4 | |
| SCHEMBL844862 | 0.79 | HRH1 (0.65) | HRH1HTR2ATAAR1KCNH2CYP3A4 | |
| SCHEMBL11883090 | 0.79 | HRH1 (0.41) | HRH1HTR2ATAAR1LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619213-B1 | MONOHYDROXY CYCLIC PHOSPHONATE SUBSTANTIALLY FREE OF POLYHYDOXY PHOSPHONATE, PROCESS FOR MAKING SAME AND FLAME RETARDANT FLEXIBLE POLYURETHANE FOAM OBTAINED THEREFROM | ICL IP AMERICA INC (US) | 2014-09-03 | — | — | EP | claimed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | claimed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | claimed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | claimed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | claimed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | claimed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | claimed |
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | claimed |
| US-20070187847-A1 | Process for the preparation of pure aryllithium compounds and their use | EMMEL UTE | 2007-08-16 | — | — | US | claimed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | claimed |
| EP-0686150-A1 | Process for the preparation of C-nucleosides and C-nucleoside analogues, new C-nucleosides and C-nucleoside analogues and their use | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 1995-12-13 | — | — | EP | claimed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| WO-1994019327-A1 | NUCLEOSIDES, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS AND AS BUILDING BLOCKS OF SYNTHETIC OLIGONUCLEOTIDES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1994-09-01 | — | — | WO | claimed |
| US-5288905-A | Glycyl urea derivatives as anti-convulsants | G. D. SEARLE & CO. (US) | 1994-02-22 | — | — | US | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0237226-B1 | PRESSURE-SENSITIVE RECORD MATERIAL | APPLETON PAPERS INC. (US) | 1990-10-10 | — | — | EP | claimed |
| US-4677211-A | Preparation of lactones | SANDOZ PHARMACEUTICALS CORP. (US) | 1987-06-30 | — | — | US | claimed |
| US-4631286-A | MEMORY ENHANCERS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-12-23 | — | — | US | claimed |
| EP-0168626-A1 | Composition for the manufacture of a medicament for the therapeutic treatment of trauma of the skin | BAR-ILAN UNIVERSITY (IL) | 1986-01-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | HRH1 379/4885HTR2A 2429/4885TAAR1 4177/4885 |
| US-20070187847-A1 | Process for the preparation of pure aryllithium compounds and their use | TYR, MLLT3, MLLT1 | HRH1 3474/4885HTR2A 2944/4885TAAR1 704/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | HRH1 379/4885HTR2A 2429/4885TAAR1 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.